Mony Chenda Morisse
Sanofi (United States)(US)
Publications by Year
Research Areas
Glioma Diagnosis and Treatment, CAR-T cell therapy research, Brain Metastases and Treatment, Lymphoma Diagnosis and Treatment, Cancer Genomics and Diagnostics
Most-Cited Works
- → Adaptation to DNA damage checkpoint in senescent telomerase-negative cells promotes genome instability(2018)61 cited
- → Interactions between tumor-associated macrophages and tumor cells in glioblastoma: unraveling promising targeted therapies(2018)61 cited
- → ERK1/2 signaling regulates the immune microenvironment and macrophage recruitment in glioblastoma(2019)38 cited
- → Squamous Cell Carcinoma Antigen-encoding Genes SERPINB3/B4 as Potentially Useful Markers for the Stratification of HNSCC Tumours(2018)18 cited
- → Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial.(2021)16 cited
- → Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study(2019)15 cited
- → Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis(2024)11 cited
- → Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment(2017)10 cited
- → Combining genomic analyses with tumour-derived slice cultures for the characterization of an EGFR-activating kinase mutation in a case of glioblastoma(2018)7 cited
- → EFFICACY AND SAFETY OF TISAGENLECLEUCEL (TISA‐CEL) IN ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): PRIMARY ANALYSIS OF THE PHASE 2 ELARA TRIAL(2021)6 cited